Dr Bupathi on Updates in the Second-Line Management of Advanced RCC
Manojkumar Bupathi, MD, MS, discusses updates in the second-line management of metastatic renal cell carcinoma and anticipated research in this space.
Dr Bupathi on Treating Patients With RCC in Community vs Academic Settings
Manojkumar Bupathi, MD, MS, discusses treating patients with renal cell carcinoma in community vs academic settings.
Dr. Bupathi on the Evolving Treatment Landscape of Bladder Cancer
Manojkumar Bupathi, MD, MS, discusses the evolving treatment landscape of bladder cancer.
Dr. Bupathi on Considerations for Second-Line Sequencing in RCC
Manojkumar Bupathi, MD, MS, discusses considerations for second-line treatment sequencing in clear cell renal cell carcinoma.
Dr. Bupathi on First-Line Treatment Options for Clear Cell RCC
Manojkumar Bupathi, MD, MS, discusses the improvement in first-line treatment options for patients with clear cell renal cell carcinoma.
Continued ADC Development in NSCLC Necessitates Improved Knowledge of Mechanisms and Biomarker Optimization
Neoadjuvant vs Perioperative Immune Checkpoint Blockade in Resectable NSCLC: How Do We Choose?
EGFR TKI–Based Combinations May Revolutionize Frontline EGFR+ NSCLC Management
Dr Olazagasti on a Case-Based Discussion of ALK-Mutated NSCLC Treatment
2 Commerce Drive Cranbury, NJ 08512